What's Happening?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. presented pivotal Phase II study results for their next-generation selective RET inhibitor, lunbotinib fumarate, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The
study focused on patients with advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). The trial included 71 pre-treated patients and 92 treatment-naïve patients. Results showed a confirmed objective response rate of 81.3% in treatment-naïve patients and 87.1% in pre-treated patients. The study also highlighted significant intracranial efficacy, with a 30% complete response rate among patients with central nervous system metastases. Lunbotinib fumarate was well tolerated, with most adverse events being mild. The New Drug Application for lunbotinib fumarate has been accepted by China's National Medical Products Administration for treating RET fusion-positive NSCLC.
Why It's Important?
The presentation of these results at ASCO 2026 underscores the potential of lunbotinib fumarate as a significant advancement in the treatment of RET fusion-positive NSCLC, a condition with limited effective treatment options. The high response rates and manageable safety profile suggest that lunbotinib could become a vital therapy for patients with this type of lung cancer, particularly those with central nervous system metastases. This development could influence treatment protocols and improve outcomes for a patient population that often faces poor prognoses. Additionally, the acceptance of the New Drug Application in China marks a critical step towards broader availability, potentially impacting global cancer treatment landscapes.
What's Next?
Following the presentation of these promising results, the next steps involve the review of the New Drug Application by China's National Medical Products Administration. If approved, lunbotinib fumarate could soon be available for patients with RET fusion-positive NSCLC in China. Additionally, ongoing clinical trials in the United States, United Kingdom, Europe, and the United Arab Emirates will further evaluate the drug's efficacy and safety, potentially leading to regulatory submissions in these regions. The outcomes of these trials could pave the way for international commercialization and integration into standard treatment regimens.
